Sugi Predict

Sugi Predict / Compounds / SCHEMBL7453142

SCHEMBL7453142

SCHEMBL7453142

Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 10/20 1.00
▸ MEN1 O00255 1/20 1.00
▸ MAPT P10636 1/20 1.00
▸ KMT2A Q03164 1/20 1.00
▸ FLT1 P17948 4/20 0.58
▸ RET P07949 4/20 0.58
▸ FGFR1 P11362 3/20 0.58
▸ KIF5B P33176 3/20 0.58
▸ RAF1 P04049 1/20 0.52
▸ BRAF P15056 1/20 0.52
▸ EGFR P00533 9/20 0.50
▸ ERBB2 P04626 5/20 0.50
▸ ERBB4 Q15303 2/20 0.49
▸ CHEK2 O96017 1/20 0.49
▸ ROS1 P08922 1/20 0.49
▸ FLT3 P36888 1/20 0.49
▸ AURKB Q96GD4 1/20 0.49
▸ CLK4 Q9HAZ1 1/20 0.49
▸ MKNK2 Q9HBH9 1/20 0.49
▸ FLT4 P35916 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29376687 1.00 KDR (1.00) KDRMEN1MAPTKMT2AFLT1
Hydrochloric Acid SCHEMBL29366626 0.99 KDR (0.98) KDRMEN1MAPTKMT2AFLT1
Hydrochloric Acid SCHEMBL7453180 0.99 KDR (0.98) KDRMEN1MAPTKMT2AFLT1
Hydrochloric Acid SCHEMBL29794574 0.99 KDR (0.98) KDRMEN1MAPTKMT2AFLT1
SCHEMBL7449934 0.91 KDR (0.84) KDRMEN1MAPTKMT2AFLT1
Hydrochloric Acid SCHEMBL7456393 0.90 KDR (0.82) KDRMEN1MAPTKMT2AFLT1
SCHEMBL7454612 0.88 KDR (0.79) KDRMEN1MAPTKMT2AFLT1
Hydrochloric Acid SCHEMBL7457129 0.87 KDR (0.78) KDRMEN1MAPTKMT2AFLT1
SCHEMBL7452840 0.85 KDR (0.79) KDRMEN1MAPTKMT2AFLT1
SCHEMBL5958966 0.84 KDR (0.80) KDRMEN1MAPTKMT2AFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250230208-A1 METHODS FOR TREATING EYE DISEASES USING LIPID BINDING PROTEIN-BASED COMPLEXES ABIONYX PHARMA SA (FR) 2025-07-17 — — US claimed
EP-4504150-A1 METHODS FOR TREATING EYE DISEASES USING LIPID BINDING PROTEIN-BASED COMPLEXES Abionyx Pharma SA (FR) 2025-02-12 — — EP claimed
US-20240000948-A1 METHODS FOR TREATING EYE DISEASES USING LIPID BINDING PROTEIN-BASED COMPLEXES ABIONYX PHARMA SA (FR) 2024-01-04 — — US claimed
WO-2023194797-A1 METHODS FOR TREATING EYE DISEASES USING LIPID BINDING PROTEIN-BASED COMPLEXES ABIONYX PHARMA SA (FR) 2023-10-12 — — WO claimed
EP-4221686-A2 COMPOSITIONS COMPRISING LIPID BINDING PROTEIN-BASED COMPLEXES FOR USE FOR TREATING EYE DISEASES Abionyx Pharma SA (FR) 2023-08-09 — — EP claimed
CN-116322646-A Compositions comprising lipid binding protein-based complexes for the treatment of ocular diseases 阿比奥尼克斯制药公司 2023-06-23 — — CN claimed
WO-2022069942-A2 METHODS FOR TREATING EYE DISEASES USING LIPID BINDING PROTEIN-BASED COMPLEXES ABIONYX PHARMA SA (FR) 2022-04-07 — — WO claimed
CN-1133625-C Quinazoline derivatives — 2004-01-07 — — CN claimed
US-20020032208-A1 Chemical compounds ZENECA LIMITED 2002-03-14 — — US claimed
EP-0873319-B1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2001-07-25 — — EP claimed
US-5962458-A ANGIOGENESIS INHIBITORS, ANTICANCER AGENTS, ANTIDIABETIC AGENTS, SKIN DISORDERS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, VISION DEFECTS ZENECA LIMITED (GB) 1999-10-05 — — US claimed
CN-1205694-A Quinazoline derivatives ZENECA LTD (GB) 1999-01-20 — — CN claimed
EP-0873319-A1 QUINAZOLINE DERIVATIVES ZENECA LIMITED (GB) 1998-10-28 — — EP claimed
WO-1997022596-A1 QUINAZOLINE DERIVATIVES ZENECA LIMITED (GB) 1997-06-26 — — WO claimed
US-20260137805-A1 SOLID CYCLODEXTRIN COMPLEXES FOR OPHTHALMIC ACTIVE PHARMACEUTICAL INGREDIENT DELIVERY Oculis Operations Sàrl (CH) 2026-05-21 — — US disclosed
US-12521448-B2 Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery Oculis Operations Sàrl (CH) 2026-01-13 — — US disclosed
US-20250230208-A1 METHODS FOR TREATING EYE DISEASES USING LIPID BINDING PROTEIN-BASED COMPLEXES ABIONYX PHARMA SA (FR) 2025-07-17 — — US disclosed
CN-1205694-A Quinazoline derivatives ZENECA LTD (GB) 1999-01-20 — — CN disclosed
EP-0873319-A1 QUINAZOLINE DERIVATIVES ZENECA LIMITED (GB) 1998-10-28 — — EP disclosed
WO-1997022596-A1 QUINAZOLINE DERIVATIVES ZENECA LIMITED (GB) 1997-06-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240000948-A1 METHODS FOR TREATING EYE DISEASES USING LIPID BINDING PROTEIN-BASED COMPLEXES CETP, HDLBP, APOB KDR 2663/4885MEN1 3759/4885MAPT 1358/4885
US-20260137805-A1 SOLID CYCLODEXTRIN COMPLEXES FOR OPHTHALMIC ACTIVE PHARMACEUTICAL INGREDIENT DELIVERY CFD, PDE6D, PDE6H KDR 731/4885MEN1 3361/4885MAPT 985/4885
US-20020032208-A1 Chemical compounds FLT1, CNKSR1, KDR KDR 3/4885MEN1 4009/4885MAPT 4765/4885
US-20250230208-A1 METHODS FOR TREATING EYE DISEASES USING LIPID BINDING PROTEIN-BASED COMPLEXES CETP, HDLBP, APOB KDR 2640/4885MEN1 4013/4885MAPT 1584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.